Hetero launches Favipiravir in India

Hetero group has announced the launch of generic Favipiravir in India under the brand ‘Favivir’ for the treatment of mild to moderate Covid-19 following the approvals from the Drug Controller General of India (DCGI) to manufacture and market the generic drug.This is the second drug developed by Hetero after Covifor, the generic version of Remdesivir injection to be administered intravenously in a hospital for treatment of severe Covid-19, under the license from Gilead Sciences.The Hyderabad headquartered generic pharmaceuticals group, which is also the world’s largest producer of antiretroviral drugs, said Favivir improves treatment accessibility to a significant amount of Covid-19 patient population, which usually sustains mild to moderate symptoms.Hetero said its generic favipiravir drug is priced at Rs 59 a tablet and is being marketed and distributed by Hetero Healthcare. The company said the product was being made available at all retail medical outlets and hospital pharmacies across the country to be sold on prescription.Further, the company said the drug is being manufactured at its world-class formulation facility, which was approved by the stringent global regulatory authorities such as the USFDA and the EU, among others, backed by strong vertical integration capabilities.Hetero, with interests across active pharmaceutical ingredients, generics, biosimilars, custom pharmaceutical services and branded generics, currently has 36 modern manufacturing facilities located across the world with approvals from global regulatory authorities.The portfolio of Hetero includes over 300 products encompassing key therapeutic categories that include HIV/AIDS, oncology, cardiovascular, neurology, hepatitis, nephrology, urology, diabetes, ophthalmology, hepatology, and immunology, among others. The company has a presence in 126 countries across the globe.